The use of cytotoxic agents and targeted therapies forms the mainstay of therapy for patients with metastatic or unresectable disease [12] As a novel targeted therapeutic agent, apatinib targets VEGFR signaling, which is frequently implicated in angiosarcoma. Here, KDR is linked to angiosarcoma.